Hypertrophic cardiomyopathy (HCM)

FDA approves Bristol Myers’ oral heart disease drug

Approvals, Boxed Warning, Bristol Myers Squibb, Cardiac Arrest, Cardiac myosin inhibitors, FDA, Genetic Inflammatory Conditions, Heart Disease, Heart Muscles, Hypertrophic cardiomyopathy (HCM), Left Ventricular Ejection Fraction (LVEF), Oral Therapy, Therapeutics, Wholesale Acquisition Cost

The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s oral heart disease drug, making Camzyos (mavacamten) the first cardiac myosin inhibitor to be permitted for use in the country.

April 28, 2022/by Reuters Health

BMS Presents Robust Mavacamten Results in HCM Ahead of FDA Decision

Bristol Myers Squibb, Cardiac myosin inhibitors, Cardiovascular Disease, Clinical Trials, Hypertrophic cardiomyopathy (HCM), R&D, R&D, Research & Development

Bristol Myers Squibb announced results from an extended study to evaluate the long-term effects of taking the cardiovascular drug mavacamten.

April 4, 2022/by BioSpace

Bristol-Myers Squibb Strengthens Cardiovascular Business with $13.1 Billion MyoKardia Buyout

Acquisitions, Business, Cardiology, Cardiovascular, Clinical Trial Endpoints, Clinical Trials, Hypertrophic cardiomyopathy (HCM), Product Pipelines, R&D

Only a year after buying cancer specialist Celgene for $74 billion, Bristol Myers Squibb announced the acquisition of cardiology company MyoKardia for about $13.1 billion.

October 5, 2020/by Andrew Humphreys

Sanofi Unloads Programs to Acer Therapeutics and MyoKardia

Business, Dilated cardiomyopathy (DCM), Ehlers-Danlos Syndrome (EDS), FDA, FDA/Regulatory, Hypertrophic cardiomyopathy (HCM), New Drug Application (NDA), Rare Diseases, Schizophrenia, Selective NK3 Receptor, Vascular Ehlers-Danlos Syndrome (EDS)

Acer Therapeutics in-licensed the clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist osanetant from Sanofi. MyoKardia regained global rights to all the programs that the company had inked with Sanofi.

January 2, 2019/by BioSpace